Nightingale Health

3,11

EUR

+2,3 %

4.592 følger denne virksomhed

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview

Finansielt overblik og estimater

Investor consensus

+2,3%

+19,62%

+7,99%

+7,99%

-2,51%

+199,04%

+38,53%

-

-39,61%

Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.

Markedsværdi

189,49 mio. EUR

Aktieomsætning

50,51 t EUR

P/E (adj.) (25e)

-11,6

EV/EBIT (adj.) (25e)

-7,8

P/B (25e)

2,72

EV/S (25e)

25,95

Udbytteafkast, % (25e)

-

Coverage

Anbefaling

Akkumulér

Kursmål

2.90 EUR

Opdateret

07.03.2025

Antti Luiro

Head of Nordic ER Development, Analyst

Latest research

Seneste analyse

Released: 07.03.2025

Seneste omfattende analyse

Released: 05.06.2023

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Risiko

Business risk

Valuation risk

Lav

Høj

Alle

Analyse

Selskabspræsentationer

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse21.3.2025, 11.00

Trading in Nightingale Health's B shares and ADRs begins on 21 March 2025 on the OTCQX International Market in the US

Nightingale Health

Selskabsmeddelelse18.3.2025, 09.30

Nightingale Health Plc's listing application has been approved and trading in its Series B shares on the Main Market of Nasdaq Helsinki will commence on 19 March 2025

Nightingale Health

Analytikerkommentar18.3.2025, 06.59 af

Nightingale OTC trading in the US likely to start already within a week

The news is expected, although OTC trading will start sooner than expected after the move to the main list.

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse17.3.2025, 14.15

The Finnish Financial Supervisory Authority has approved Nightingale Health Plc's Finnish prospectus

Nightingale Health

Selskabsmeddelelse17.3.2025, 11.55

Nightingale Health establishes ADR program in the US - trading in Company's B shares and ADRs begins on 19 March 2025, at the earliest, and 24 March 2025, at the latest, on the OTCQX Market in the US

Nightingale Health

Analytikerkommentar13.3.2025, 06.16 af

Nightingale applies for its shares to be listed on the Main Market of Nasdaq Helsinki

The submission of the application for moving to the main list was expected, as the company announced in November that it was looking into it.

Nightingale Health

Selskabsmeddelelse12.3.2025, 12.30

Nightingale Health Plc applies for its series B shares to be listed on the Main Market of Nasdaq Helsinki

Nightingale Health

Nightingale H1'FY25: Blood draws again

Analyse7.3.2025, 09.45 af

Nightingale H1'FY25: Blood draws again

Nightingale is just launching the commercial phases with its second and third healthcare partners. The company's comments on the sales pipeline are also promising, and we believe it will announce at least one significant partnership during the current year.

Nightingale Health

Nightingale, Webcast, Q2'25

Videopræsentation6.3.2025, 12.00

Nightingale, Webcast, Q2'25

Nightingale Health

Selskabsmeddelelse6.3.2025, 07.00

Nightingale Health's half-year report: International expansion continues in Southeast Asia and the United States

Nightingale Health

Nightingale H1’FY25 preview: Maturing the next wave of pilots

Analytikerkommentar5.3.2025, 07.38 af

Nightingale H1’FY25 preview: Maturing the next wave of pilots

Driven by the Terveystalo partnership, which was successfully launched at the beginning of 2024, revenue is on an upward trend compared to the previous year.

Nightingale Health

Pressemeddelelse28.2.2025, 10.35

Nightingale Health to publish half-year report for July - December 2024 on 6 March 2025

Nightingale Health

Pressemeddelelse27.2.2025, 12.15

Nightingale Health announces the development of innovative LLM based tool to empower anyone to take informed decisions to lower disease risks

Nightingale Health

Analytikerkommentar10.2.2025, 07.42 af

Nightingale's path to regulatory approval in the US is becoming clearer and progressing

As promised, Nightingale provided further information on plans to obtain regulatory approvals in the US on Friday.

Nightingale Health

Pressemeddelelse7.2.2025, 12.15

Nightingale Health announces its updated regulatory plan in the United States

Nightingale Health

Analytikerkommentar27.1.2025, 10.47 af

Nightingale Health enters Middle East collaboration

Nightingale has signed a pilot agreement and letter of intent with Enigma Genomics to use the company's Remote Health Check in a full-scale commercial operation for Enigma's clients in Saudi Arabia and the wider MENA region.

Nightingale Health

Pressemeddelelse27.1.2025, 07.00

Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region

Nightingale Health

Analytikerkommentar24.1.2025, 07.46 af

Nightingale Health published new disease risk assessments

Nightingale announced that it has published two new disease risk assessments for its Health Check service: fatty liver disease and stroke.

Nightingale Health

Pressemeddelelse23.1.2025, 09.00

Nightingale Health announces the performance metrics of its latest generation disease risk assessments to be rolled out in Singapore and the United States

Nightingale Health

Selskabsmeddelelse23.12.2024, 12.00

Conversion of Nightingale Health Plc's EMP shares to Series B shares

Nightingale Health

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.